Clinical Scorecard: Presbyopia Drops, a Promising Solution

At a Glance

Key Highlights

• FDA-approved treatments include Pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity) and 0.4% (Qlosi).
• Presbyopia drops provide a non-invasive alternative to glasses and surgery.
• Effective patient selection and education are critical for optimal outcomes.
• Common side effects include headaches and eye irritation.
• Newer ophthalmic drugs for presbyopia are in trials, with potential for reduced side effects.

Guideline-Based Recommendations

Diagnosis

• Conduct a thorough eye examination to assess presbyopia severity and patient suitability.

Management

• Presbyopia drops should be considered for patients not interested in or not candidates for surgical options.

Monitoring & Follow-up

• Regular follow-up to assess vision improvement and side effects.

Risks

• Screen for retinal conditions before prescribing due to potential increased risk of retinal complications.

Patient & Prescribing Data

Patients aged 40 and older, particularly those with early to moderate presbyopia.

Vuity is effective for functional near vision when used consistently; Qlosi offers similar benefits with a lower concentration.

Clinical Best Practices

• Educate patients on the temporary nature of the drops and the importance of adherence to the regimen.
• Provide clear communication scripts for staff to ensure consistent patient education.
• Utilize strategies to enhance patient adherence, such as digital reminders and daily usage logs.

References

• Clinical Trials for Vuity and Qlosi
• FDA Approval Information